G12.0 Insurance Policy Changes

ICD-10 G12.0 is officially defined as "Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]." code G12.0 is referenced in 7 tracked payer policy changes from Blue Cross of Idaho, Excellus BlueCross BlueShield, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code G12.0 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross of Idaho · Effective Dec 1, 2026Medium impact
MP 5.01.28 Treatment for Spinal Muscular Atrophy - Concurrent use of risdiplam with onasemnogene abeparvovec-xioi and/or nusinersen is considered investigational.
Concurrent use of risdiplam with onasemnogene abeparvovec-xioi and/or nusinersen is considered investigational, as is concurrent use of nusinersen or onasemnogene abeparvovec-xioi with the other therapies, and use of nusinersen or risdiplam after onasemnogene abeparvovec-xioi. Nusinersen, onasemnogene abeparvovec-xioi and risdiplam may be considered medically necessary when all of their listed conditions are met, and the current version ends 11/30/2026 while a pending version takes effect 12/01/2026.
Excellus BlueCross BlueShield · Effective Oct 15, 2026Medium impact
Continuous Positive Airway Pressure (CPAP) and Auto-Adjusting Positive Airway Pressure (APAP) Devices - (Effective Date - 2026-10-15) 1.01.06
Excellus BlueCross BlueShield medical policy 1.01.06 on CPAP and APAP devices has a current effective date of October 15, 2026. The June 18, 2026 revision removed BiPAP and non-invasive ventilator criteria and their associated codes from this policy and placed them in new medical policy 1.01.57, Home Non-Invasive Positive Pressure Ventilation (NIPPV) Devices for Respiratory Insufficiency and Failure. The policy covers CPAP and APAP for adults with obstructive sleep apnea whose AHI or RDI is above 5 and below 15 with an associated symptom or cardiovascular disease, or whose AHI or RDI is 15 or more, and it covers continued use after the initial 90-day trial only when AHI and symptoms improved and compliance is shown.
Independence Blue Cross · Effective Mar 23, 2026Medium impact
08.01.36f, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)
Independence Blue Cross updated policy 08.01.36f to version 08.01.36i, effective 03/23/2026. Zolgensma eligibility expanded to include SMA Types 0-3, removing the previous requirement to document 2 or fewer SMN2 gene copies. Two ICD-10 diagnosis codes (G12.0 and G12.1) were removed from the policy. Experimental and investigational sections were revised for clarity with no intent changes.
Aetna · Identified Aug 17, 2026Medium impact
Ambulatory Assist Devices: Canes, Crutches, and Walkers (CPB 0505, reviewed 2026-08-03)
Aetna considers canes, crutches, and walkers medically necessary durable medical equipment when the member has a mobility limitation that significantly impairs participation in one or more mobility-related activities of daily living (MRADL) in the home, the member can safely use the device, and the functional deficit can be sufficiently resolved by the device. Axillary, articulated, spring-assisted crutches, sit-and-stand walking assistant crutches, walkers with enclosed frames, walking belts, and standard strollers are not considered medically necessary, and enhancement accessories such as style, color, seat attachments, tray attachments, baskets, or cup holders are not covered. The AutoAmbulator, battery or electronic powered walkers such as the Sully Walker, the Upsee mobility device, and the wearable freezing of gait detection system are considered experimental, investigational, or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Onasemnogene Abeparvovec (Zolgensma and Itvisma) (CPB 0953, reviewed 2026-08-10)
Aetna's clinical policy bulletin covers onasemnogene abeparvovec (Zolgensma and Itvisma) for commercial medical plans and requires precertification of all Aetna participating providers and members in applicable plan designs. Aetna considers Zolgensma medically necessary as a single-dose intravenous infusion for spinal muscular atrophy (SMA) when the member is less than 2 years of age, has a genetically confirmed diagnosis with bi-allelic SMN1 variants and 3 or fewer copies of SMN2, and meets the other listed criteria, and considers Itvisma medically necessary as a single intrathecal dose for SMA when the member is 2 to less than 18 years of age, had onset of signs and symptoms at 6 months of age or older, and meets the other listed criteria. Aetna considers both products experimental, investigational, or unproven for all other indications, and considers repeat administration of onasemnogene abeparvovec experimental, investigational, or unproven.
Independence Blue Cross · Identified Jun 19, 2026Low impact
MA08.086d, Nusinersen (Spinraza®)
Independence Blue Cross has reissued Medical Policy MA08.086d for Nusinersen (Spinraza®) as part of its annual review process. The policy establishes coverage criteria for this spinal muscular atrophy treatment under Medicare Advantage plans, requiring genetic confirmation of 5q-SMA, prescription by a neurologist/physiatrist, and documented motor function improvement on standardized scales for continuation therapy. No substantive coverage changes were noted in this reissuance.
Independence Blue Cross · Identified Jun 19, 2026Low impact
MA08.086d, Nusinersen (Spinraza®)
Independence Blue Cross reissued Medicare Advantage policy MA08.086d for Nusinersen (Spinraza®) on March 4, 2026, as part of the annual review process. The policy establishes coverage criteria for treating spinal muscular atrophy types 1, 2, 3, and presymptomatic types 1-2, requiring genetic confirmation, specialist prescription, specific dosing regimens, and documented motor function improvement for continuation therapy. No substantive coverage changes are indicated from prior versions; this is a routine annual renewal with the same medical necessity criteria and dosing parameters remaining in effect.

Watch G12.0

Get one email when a payer policy names G12.0, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code G12.0?

There are 7 tracked policy changes affecting code G12.0, including updates from Blue Cross of Idaho, Excellus BlueCross BlueShield, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code G12.0?

Payers that have issued tracked updates for code G12.0 include: Blue Cross of Idaho, Excellus BlueCross BlueShield, Independence Blue Cross, Aetna.

How do I get notified when code G12.0 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code G12.0. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code G12.0?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

MP 5.01.28 Treatment for Spinal Muscular Atrophy - Concurrent use of risdiplam with onasemnogene abeparvovec-xioi and/or nusinersen is considered investigational.

Continuous Positive Airway Pressure (CPAP) and Auto-Adjusting Positive Airway Pressure (APAP) Devices - (Effective Date - 2026-10-15) 1.01.06

08.01.36f, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)

Ambulatory Assist Devices: Canes, Crutches, and Walkers (CPB 0505, reviewed 2026-08-03)

Onasemnogene Abeparvovec (Zolgensma and Itvisma) (CPB 0953, reviewed 2026-08-10)

MA08.086d, Nusinersen (Spinraza®)

MA08.086d, Nusinersen (Spinraza®)

What insurance policy changes affect code G12.0?

Which payers have updated policy for code G12.0?

How do I get notified when code G12.0 policy changes?

Why do payers change policies for code G12.0?